Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 2:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–20 of 20 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cat Allergy Clear all
Not listed Phase 1 Interventional

Airway Immune Response to Allergens (Use Lay Language Here)

NCT04619017
View directory record Official record
Conditions
Allergic Asthma, Allergy to Cats, Allergy to Dust Mites, Allergic Rhinitis, Allergic Conjunctivitis
Interventions
Segmental allergen challenge
Biological
Lead sponsor
JOSALYN CHO
Other
Eligibility
18 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Iowa City, Iowa • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 30, 2023 · Synced Sep 6, 2026, 2:18 AM EDT
Completed Not applicable Interventional Results available

The Effect of Omalizumab on Responses to Cat Allergen Challenge

NCT00604786
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
omalizumab, placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 50 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Sep 6, 2026, 2:18 AM EDT
Completed Phase 3 Interventional Results available

Phase III Cat-PAD Study

NCT01620762
View directory record Official record
Conditions
Rhinoconjunctivitis
Interventions
Cat-PAD, Placebo
Drug
Lead sponsor
Circassia Limited
Industry
Eligibility
12 Years to 65 Years
Enrollment
1,408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
52
States / cities
Rolling Hills Estates, California • Colorado Springs, Colorado • Denver, Colorado + 49 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Sep 6, 2026, 2:18 AM EDT
Recruiting Early Phase 1 Interventional

LYmph Node eXamination in Cat Allergen Immunotherapy

NCT07447869
View directory record Official record
Conditions
Allergy
Interventions
Intradermal cat allergen challenge
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 6, 2026, 2:18 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Fel d 1 Monoclonal Antibodies in Adult and Pediatric Participants With Allergic Conjunctivitis Due to Cat Allergy

NCT07675811
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
REGN-2Cat, Freneslerbart, Mevonlerbart, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
8 Years and older
Enrollment
570 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 6, 2026, 2:18 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Examine the Efficacy and Safety of Anti-Fel d 1 Antibodies Injections in Cat-allergic Adolescent and Adult Patients With Allergic Rhinitis Who Live With a Cat

NCT04981717
View directory record Official record
Conditions
Allergic Rhinitis Due to Cat Allergy
Interventions
REGN1908-1909, Matching Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
446 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
42
States / cities
Mission Viejo, California • Riverside, California • Rolling Hills Estates, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2024 · Synced Sep 6, 2026, 2:18 AM EDT
Completed Not applicable Interventional Results available

Imaging Study of the Lungs During an Allergic Asthma Attack

NCT01547286
View directory record Official record
Conditions
Asthma, Atopy
Interventions
Standardized Cat Allergen Extract and Standardized Dust Mite Allergen, Computed Tomography imaging, functional Positron Emission Tomography imaging, Nebulized methacholine inhalation
Biological · Radiation · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 21, 2017 · Synced Sep 6, 2026, 2:18 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

abioSCOPE IgE Assay to Aid in the Diagnosis of Allergies

NCT04442932
View directory record Official record
Conditions
Allergy, Allergic Asthma, Allergy to Cats, Allergy to House Dust, Allergy to Dog Dander, Allergy Cockroach
Interventions
Blood Collection
Device
Lead sponsor
Abionic SA
Industry
Eligibility
6 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Crownsville, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2020 · Synced Sep 6, 2026, 2:18 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

The Effects of Omalizumab (Anti-IgE) on the Late-phase Response to Nasal Allergen Challenge

NCT01003301
View directory record Official record
Conditions
Cat Allergy
Interventions
Omalizumab, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 50 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 6, 2014 · Synced Sep 6, 2026, 2:18 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Anti-TSLP (AMG 157) Plus Antigen-Specific Immunotherapy for Induction of Tolerance in Individuals With Cat Allergy

NCT02237196
View directory record Official record
Conditions
Cat Allergy, Cat Hypersensitivity
Interventions
AMG 157, Cat Immunotherapy, Cat Immunotherapy Placebo, AMG 157 Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
9
States / cities
Los Angeles, California • Denver, Colorado • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated May 5, 2020 · Synced Sep 6, 2026, 2:18 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Analytical Validation of the abioSCOPE Device With an IgE Test Panel: Point-of-Care Precision, Sample Type Comparison and Method Correlation

NCT04401631
View directory record Official record
Conditions
Allergy, Allergic Asthma, Allergy to Cats, Allergy to House Dust, Allergy to Dog Dander (Finding), Allergy Mold, Allergy Cockroach
Interventions
Blood Collection
Device
Lead sponsor
Abionic SA
Industry
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 4, 2020 · Synced Sep 6, 2026, 2:18 AM EDT
Completed Phase 3 Interventional

A Study to Demonstrate How Well REGN1908-1909 Works in Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Cat Allergy

NCT06602726
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
REGN1908, REGN1909, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 6, 2026, 2:18 AM EDT
Completed No phase listed Observational

Making Sense of Dyspnea Assessment

NCT02771262
View directory record Official record
Conditions
COPD, Dyspnea
Interventions
Pulmonary Rehabilitation
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
40 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 27, 2020 · Synced Sep 6, 2026, 2:18 AM EDT
Completed Phase 4 Interventional Results available

Study of Two Marketed Ocular Anti-Allergy Medications in Subjects With Allergic Conjunctivitis

NCT00534794
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Elestat, Pataday
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 12, 2015 · Synced Sep 6, 2026, 2:18 AM EDT
Withdrawn No phase listed Observational

Diesel Exhaust Particles and Leukotriene Production

NCT00915447
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Sep 6, 2026, 2:18 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Viral Mucosal Reprogramming

NCT05331170
View directory record Official record
Conditions
Asthma, Allergic Rhinitis, Cat Allergy, Healthy
Interventions
Research Grade RG-RV
Biological
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 60 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Sep 6, 2026, 2:18 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study in Adults Sensitized to Cat

NCT00689299
View directory record Official record
Conditions
Allergy
Interventions
Standardized Allergenic Extract, Cat Hair, Placebo
Biological
Lead sponsor
Antigen Laboratories, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
3
States / cities
San Diego, California • Marietta, Georgia • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 30, 2014 · Synced Sep 6, 2026, 2:18 AM EDT
Completed Phase 2 Interventional

The Effect of Nasal Carbon Dioxide (CO2) on Nasal Congestion in Subjects With Perennial Allergic Rhinitis

NCT00638755
View directory record Official record
Conditions
Perennial Allergic Rhinitis
Interventions
Nasal Carbon Dioxide
Drug
Lead sponsor
Capnia, Inc.
Industry
Eligibility
19 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 18, 2010 · Synced Sep 6, 2026, 2:18 AM EDT
Completed Phase 2 Interventional Results available

Phase II HDM-SPIRE Safety and Efficacy Study

NCT02150343
View directory record Official record
Conditions
Rhinoconjunctivitis
Interventions
HDM-SPIRE, Placebo
Drug
Lead sponsor
Circassia Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
715 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
56
States / cities
Birmingham, Alabama • Huntington Beach, California • Long Beach, California + 53 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Sep 6, 2026, 2:18 AM EDT
Terminated No phase listed Observational

Observational Analysis of T Cell Responses to SPIREs for Multiple Allergens in Subjects With Allergy in North America

NCT02601690
View directory record Official record
Conditions
Allergy
Interventions
Blood Sampling
Other
Lead sponsor
Adiga Life Sciences, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Upland, California • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 8, 2019 · Synced Sep 6, 2026, 2:18 AM EDT